Physician profile
George A Davis
NPI 1346210887
$2,203.05
in general payments reported to CMS, 2019-2025
17 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $116 · 2021: $459 · 2022: $429 · 2023: $214 · 2024: $507 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $483.86 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $400.36 | 2021-2025 | |
| Esperion Therapeutics, INC. | $241.12 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $171.12 | 2019-2023 | Xarelto |
| Pfizer INC. | $147.24 | 2019-2024 | |
| Biotronik INC. | $147.04 | 2025 | Amvia Edge, Biomonitor |
| E.R. Squibb & Sons, L.L.C. | $127.61 | 2019-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $95.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $82.20 | 2019-2023 | Verquvo, Belsomra |
| Lilly USA, LLC | $72.92 | 2021-2022 | |
| Amgen INC. | $55.68 | 2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $53.32 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $48.59 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $24.79 | 2024 | Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $20.99 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $18.10 | 2021 | |
| Allergan, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.